Showing results (81-90 of 238) with videos related to
Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancerLuca Gianni, Anna Lladó, Giulia Bianchi, et al.Molecular Cancer Therapeutics|March 9, 2011
Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancerMaurizio Scaltriti, Violeta Serra, Emmanuel Normant, et al.JCI Insight|March 30, 2017
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutationsPatrizia Mondello, Elliott J Brea, Elisa De Stanchina, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancerCristina Saura, Jose A Garcia-Saenz, Binghe Xu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumorsKyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapyEnriqueta Felip, Federico Rojo, Martin Reck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximabDesmond Curran, Jordi Giralt, Paul M Harari, et al.Targeted Oncology|May 13, 2014
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumabJosep Tabernero, Sant P Chawla, Hedy Kindler, et al.Cancer|September 5, 2002
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabineJoaquim Bellmunt, Joan Albanell, Luis Paz-Ares, et al.Pageof 24